Pfizer

Pfizer has agreed to pay around $400m charge for an agreement in principle to resolve a securities class action pending against the company over off-label promotion actions.

The decision was disclosed as the company released its fourth-quarter results.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The agreement is subject to New York federal court approval and has been revealed ahead of a jury trial set for 10 February, reported Reuters.

"This resolution reflects a desire by the company to avoid the distraction of continued litigation and focus on the needs of patients and physicians."

Pfizer spokeswoman Christine Regan Lindenbloom was quoted by Reuters as saying: "This resolution reflects a desire by the company to avoid the distraction of continued litigation and focus on the needs of patients and physicians."

In 2010, a lawsuit was filed against the company and various executives for giving false statements to shareholders regarding its off-label marketing of products such as Bextra.

In addition, the US drugmaker was charged for making misleading statements about different government investigations of those practices, which resulted in a $2.3bn settlement with the US Justice Department in 2009.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A Pfizer spokeswoman said that the firm continues to deny wrongdoing and that the disclosures to investors ‘were appropriate and prepared in good faith’.

Robbins Geller Rudman & Dowd lawyer for the investors Michael Dowd declined to comment on the trial.


Image: Pfizer world headquarters: Photo: courtesy of Jim.henderson.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now